Hepatology Research

Article	Citations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	159
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	105
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	81
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	62
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	57
Factors associated with portopulmonary hypertension	45
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	44
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	39
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	37
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	37
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	36
Deceased Donation Disparities in East Asia—A Tale of Two Systems	35
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	35
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	35
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	29
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	27
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	26
The change from NAFLD to MAFLD expands fatty liver information flow	25
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	23
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	23
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	22
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	21
Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation	21
Issue Information	20
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	20

	19
Issue Information	19
Issue Information	19
	18
Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	18
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	17
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	17
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	17
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	17
Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	17
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	16
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	16
Chronic liver disease questionnaire to manage patients with chronic liver diseases	16
Issue Information	15
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	15
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	15
	15
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis	15
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	15
Issue Information	15
Measurement of spleen length and two‐dimensional spleen index is comparable to spleen volumetry by computed tomography for predicting esophageal varices	14
Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures	14
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	14
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	14
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	13
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	13
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	13
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	13
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	12
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	12
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	12
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	12
Quantitative evaluation of tumor signal heterogeneity on gadoxetic acid‐enhanced magnetic resonance imaging as a predictor of postoperative survival and antitumor immunity in hepatocellular carcinoma	12
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	12
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	11
Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD	11
	11
	11
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	11
Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma	11
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	10
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	10
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	10
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	10
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	10
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	10
	10
Cost‐effectiveness of hepatitis E virus vaccination strategy	10
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation	10
	9

	9
Issue Information	9
The role of the nervous system in liver diseases	9
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	9
	9
Issue Information	9
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	9
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	9
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	9
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	9
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	8
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	8
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	8
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	8
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	8
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	8
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	8
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	8
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	8
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	8
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	8
Erratum	8
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	8
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	8
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	8
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	8
Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis	8
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	8
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	7
Issue Information	7
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	7
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	7
	7
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	7
Evaluating the liver function of patients with hepatocellular carcinoma	7
	7
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	7
Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept	7
Issue Information	7
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	7
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	7
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	7
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	6
	6
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	6
Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	6
	6
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	6
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	6
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	6
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	6
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	6
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
Issue Information	6
Metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?	6
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	6
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	6
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	6
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	6
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	6
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	6
Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study	5
Acknowledgments	5
Advancing Gene Mutation Analysis Through Post‐Ablation Liver Tumor Biopsy Specimens	5
Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations	5
A classification model for resectability in hepatocellular carcinoma patients	5
Issue Information	5
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	5
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy	5
An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	5
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	5
The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography	5
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	5
Acknowledgment	5
Clinical benefits of partial splenic embolization for cancer patients	5
Acknowledgment	5
Issue Information	5
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	5
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	5
Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers	5

Issue Information	5
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	5
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	5
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade	5
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	5
	5
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study	5
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	5
Cachexia is an independent predictor of mortality in patients with cirrhosis	5
Pathological significance of intranuclear structures in liver biopsy samples	5
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease	5
Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma	5
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	5
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	4
Serum pro‐inflammatory cytokine interleukin‐6 level is predictive of further decompensation and mortality in liver cirrhosis	4
Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake	4
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma	4
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study	4
Exosomal circCMTM3 promotes the pathogenesis of hepatocellular carcinoma via angiogenesis	4
Corrigendum	4
	4
Identification of reversed portal flow on 4DCT and of factors contributing to reversed portal flow in patients with liver cirrhosis and portosystemic shunt before interventional radiology procedures	4
Defining advanced lymph node metastasis in intrahepatic cholangiocarcinoma: A multicenter study	4
Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease	4
The promise of radiotherapy for hepatocellular carcinoma	4
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical	4
Issue Information	4
Issue Information	4
	4
Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection	4
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease	4
Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy	4
	4
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma	4
High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma	4
Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease	3
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice	3
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	3
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma	3
Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: A Mendelian randomization study	3
Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta‐analysis	3
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients	3
Significance of a multidisciplinary approach to congenital extrahepatic portosystemic shunt: A changing paradigm for the treatment	3
Liver imaging reporting and data with perfluorobutane microbubbles—Is there hope?	3
Correction to “Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression”	3
Issue Information	3
Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis	3
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study	3
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in healt	3
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab	3
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey	3
Letter to ‘‘Circulating Myostatin Levels as a Prognostic Biomarker in Patients With Acute Liver Failure and Late‐Onset Hepatic Failure’’	3
Apparent diffusion coefficient in intrahepatic cholangiocarcinoma diffusion‐weighted magnetic resonance imaging noninvasively predicts Ki‐67 expression	3
Impact of albumin–lymphocyte–platelet–C‐reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2–related factor 2	3
	3
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity	3
Real‐world trends in acute viral hepatitis in Japan: A nationwide questionnaire‐based survey	3
Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia	3
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	3
	3
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide seq	3
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	3
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic k	3
Issue Information	3
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	3
Involvement of the ADAMTS13–von Willebrand factor axis in acute kidney injury in mice with liver cirrhosis	3
Galectin‐3 in biliary atresia and other pediatric cholestatic liver diseases	3
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab	3
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	3
Algorithm of ascites management for liver cirrhosis in the tolvaptan era: Paradigm shift treatment improves the outcomes of cirrhotic patients?	3
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	3
Issue Information	3
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	3
Issue Information	3
Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus	3
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study	3
Proximal splenic artery embolization for treatment of refractory ascites, a single‐center experience	2
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	2
Tumor‐infiltrating CD8+ T‐cell numbers and serum C‐reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab	2
Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan	2
Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection	2
Successful pediatric liver transplantation case with a positive SARS‐CoV‐2 test at the time of transplant	2
	2
Noninvasive graft monitoring using donor‐derived cell‐free DNA in Japanese liver transplantation	2
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multi	2
Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B	2
Clinical association between intraoperative indocyanine green fluorescence imaging pattern, preoperative Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging findings, and histological differentiation in h	2
Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma	2
Issue Information	2
The ratio of serum des‐gamma‐carboxy prothrombin to tumor volume as a new biomarker for early recurrence of resected hepatocellular carcinoma	2
Long‐term persistence of hepatocarcinogenic potential of a non‐hypervascular hypointense nodule on EOB‐MRI after the eradication of hepatitis C virus	2
Rare sequence variants associated with the risk of non‐syndromic biliary atresia	2
Value of liver biopsy in anorexia nervosa‐related transaminitis: A case study and literature review	2
Aspartate aminotransferase‐to‐platelet ratio index outperforms Fibrosis‐4 in 2843 Korean patients with metabolic dysfunction‐associated steatotic liver disease	2
Treatment patterns and medical costs after hepatectomy in real‐world practice for patients with hepatocellular carcinoma in Japan	2